Мурашев Аркадий Николаевич

Избранные публикации

  1. Logashina Y.A., Solstad R.G., Mineev K.S., Korolkova Y.V., Mosharova I.V., Dyachenko I.A., Palikov V.A., Palikova Y.A., Murashev A.N., Arseniev A.S., Kozlov S.A., Stensvåg K., Haug T., Andreev Y.A. (2017). New Disulfide-Stabilized Fold Provides Sea Anemone Peptide to Exhibit Both Antimicrobial and TRPA1 Potentiating Properties. Toxins (Basel) 9 (5), [+]

    A novel bioactive peptide named τ-AnmTx Ueq 12-1 (short name Ueq 12-1) was isolated and characterized from the sea anemone Urticina eques. Ueq 12-1 is unique among the variety of known sea anemone peptides in terms of its primary and spatial structure. It consists of 45 amino acids including 10 cysteine residues with an unusual distribution and represents a new group of sea anemone peptides. The 3D structure of Ueq 12-1, determined by NMR spectroscopy, represents a new disulfide-stabilized fold partly similar to the defensin-like fold. Ueq 12-1 showed the dual activity of both a moderate antibacterial activity against Gram-positive bacteria and a potentiating activity on the transient receptor potential ankyrin 1 (TRPA1). Ueq 12-1 is a unique peptide potentiator of the TRPA1 receptor that produces analgesic and anti-inflammatory effects in vivo. The antinociceptive properties allow us to consider Ueq 12-1 as a potential analgesic drug lead with antibacterial properties.

  2. Stepanov A., Belyy A., Kasheverov I., Rybinets A., Dronina M., Dyachenko I., Murashev A., Knorre V., Sakharov D., Ponomarenko N., Tsetlin V., Tonevitsky A., Deyev S., Belogurov A., Gabibov A. (2016). Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs. Biotechnol. Lett. , [+]

    Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell receptors (BCRs) would be beneficial in terms of MS treatment.

  3. Osmakov D.I., Koshelev S.G., Andreev Y.A., Dyachenko I.A., Bondarenko D.A., Murashev A.N., Grishin E.V., Kozlov S.A. (2015). Conversed mutagenesis of an inactive peptide to ASIC3 inhibitor for active sites determination. Toxicon , [+]

    Peptide Ugr9-1 from the venom of sea anemone Urticina grebelnyi selectively inhibits the ASIC3 channel and significantly reverses inflammatory and acid-induced pain in vivo. A close homolog peptide Ugr 9-2 does not have these features. To find the pharmacophore residues and explore structure-activity relationships of Ugr 9-1, we performed site-directed mutagenesis of Ugr 9-2 and replaced several positions by the corresponding residues from Ugr 9-1. Mutant peptides Ugr 9-2 T9F and Ugr 9-2 Y12H were able to inhibit currents of the ASIC3 channels 2.2 times and 1.3 times weaker than Ugr 9-1, respectively. Detailed analysis of the spatial models of Ugr 9-1, Ugr 9-2 and both mutant peptides revealed the presence of the basic-aromatic clusters on opposite sides of the molecule, each of which is responsible for the activity. Additionally, Ugr9-1 mutant with truncated N- and C-termini retained similar with the Ugr9-1 action in vitro and was equally potent in vivo model of thermal hypersensitivity. All together, these results are important for studying the structure-activity relationships of ligand-receptor interaction and for the future development of peptide drugs from animal toxins.

  4. Ilyushin D.G., Smirnov I.V., Belogurov A.A. Jr, Dyachenko I.A., Zharmukhamedova T.I.u., Novozhilova T.I., Bychikhin E.A., Serebryakova M.V., Kharybin O.N., Murashev A.N., Anikienko K.A., Nikolaev E.N., Ponomarenko N.A., Genkin D.D., Blackburn G.M., Masson P., Gabibov A.G. (2013). Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc. Natl. Acad. Sci. U.S.A. 110 (4), 1243–8 [+]

    The creation of effective bioscavengers as a pretreatment for exposure to nerve agents is a challenging medical objective. We report a recombinant method using chemical polysialylation to generate bioscavengers stable in the bloodstream. Development of a CHO-based expression system using genes encoding human butyrylcholinesterase and a proline-rich peptide under elongation factor promoter control resulted in self-assembling, active enzyme multimers. Polysialylation gives bioscavengers with enhanced pharmacokinetics which protect mice against 4.2 LD(50) of S-(2-(diethylamino)ethyl) O-isobutyl methanephosphonothioate without perturbation of long-term behavior.

  5. Хохлова О.Н., Жармухамедова Т.Ю., Гуськова Т.А., Мурашев А.Н. (2009). Добротная лабораторная практика (GLP) – основа обеспечения качества доклинических исследований. Мол. медицина 5, 42–47 ID:268
  6. Жармухамедова Т.Ю., Хохлова О.Н., Гуськова Т.А., Ржевский Д.И., Мурашев А.Н. (2009). Обязанности руководителя исследования при проведении испытаний безопасности химических веществ, биотехнологических и нанотехнологических продуктов в соответствии с правилами надлежащей лабораторной практики. Токсикол. вестник 5, 2–4 ID:269
  7. Остров В.Ф., Слащёва Г.А., Жармухамедова Т.Ю., Рожкова Е.А., Евгеньев М.Б., Мурашев А.Н. (2009). Влияние человеческого рекомбинантного и бычьего белков теплового шока (70 кДа) на гемодинамику и гемостаз при эндотоксиновом шоке у крыс. Доклады РАН 429 (5), 691–693 ID:270
  8. Ovchinnikova T.V., Murashev A.N. (2009). The peptaibol antibiotic zervamicin displays neurotropic activity. Dokl. Biochem. Biophys. 414, 146–8 ID:415
  9. Лобанова Н.Н., Медведев Н.И., Попов В.И., Мурашев А.Н. (2008). Моделирование глобальной ише-мии головного мозга путем била-теральной окклюзии сонных арте-рий у бодрствующих гипертензив-ных крыс (SHR-SP). Бюл. эксперим. биологии и медицины 146 (12), 627–630 ID:271
  10. Ovchinnikova T.V., Levitskaya N.G., Voskresenskaya O.G., Yakimenko Z.A., Tagaev A.A., Ovchinnikova A.Y., Murashev A.N., Kamenskii A.A. (2007). Neuroleptic properties of the ion-channel-forming peptaibol zervamicin: locomotor activity and behavioral effects. Chem. Biodivers. 4 (6), 1374–87 [+]

    Zervamicins IIA and IIB are members of the peptaibol family of peptide antibiotics. They are produced by the fungus Emericellopsis salmosynnemata. Peptaibols are known to be of potential usefulness for chemotherapeutic applications, as are other secondary fungal metabolites. Previously, we have found zervamicins to decrease spontaneous locomotor activity in mice, suggesting their neurotropic properties on an equal footing with antimicrobial activity. The current study deals with behavioral effects of zervamicins IIA and IIB in mice. According to our results, both zervamicins induce a reliable decrease in locomotion and exploratory activity measured in the hole-board test. The behavioral effects of zervamicin IIA become apparent at lower dosages (0.05-2.0 mg/kg) as compared with zervamicin IIB (0.5-12.0 mg/kg). The experiments on behavioral effects in the elevated plus maze test showed that both zervamicins caused a reliable decrease in the number of head-dippings, open-arm entries, and rearings. The observed behavioral effects may be rather associated with a decrease in the exploratory activity than with anxiety-related responses in mice. Zervamicins induced depression-like behavior of experimental animals in the forced-swim test. Both peptaibols reduce physical endurance and change motor coordination of experimental animals in the bar-holding test. Taken together, the data obtained clearly indicate that both zervamicins possess neuroleptic activity.

  11. Rzhevsky D.I., Zhokhov S.S., Babichenko I.I., Goleva A.V., Goncharenko E.N., Baizhumanov A.A., Murashev A.N., Lipkin V.M., Kostanyan I.A. (2005). HLDF-6 peptide affects behavioral reactions and organism functions dependent on androgen hormones in normal and castrated male mice. Regul. Pept. 127 (1-3), 111–21 [+]

    The hexapeptide Thr-Gly-Glu-Asn-His-Arg (HLDF-6), which was first identified as an active fragment of the human leukemia differentiation factor (HLDF) molecule, displays differentiation-inducing, neuroprotective and anti-drug abuse activities. Most of its in vivo effects were revealed only on male animals. We have studied HLDF-6 effects on a variety of organism functions and behavioral reactions, which are known to be dependent on androgen steroid hormones, both on castrated and normal (sham-operated) animals. Male NMRI mice were castrated or sham-operated at the age of 55 days (after puberty). After that, HLDF-6 peptide was injected daily during 3 weeks, followed by behavioral, morphological and biochemical testing. HLDF-6 increased testosterone level (1.5- to 2-fold) both in sham-operated and castrated animals. Sexual activity and pain sensitivity, which are strongly reduced in castrates, were completely or partially recovered by HLDF-6. At the same time, the peptide caused some effects similar to castration in sham-operated animals: aggression and locomotor activity were decreased; oral grooming was prolonged. Morphological studies of accessory sex glands showed that HLDF-6 partially normalizes the morphology and functional activity of seminal vesicles in castrates, but it does not prevent castration-induced apoptosis of prostate epithelial cells. Based on these observations, we can assume that HLDF-6 peptide displays at least two effects on androgen hormones metabolism in males: it stimulates testosterone biosynthesis by both testes and adrenals and simultaneously inhibits its conversion to dihydrotestosterone (DHT), most probably by diminution of 5alpha-reductase isoform 1 mRNA expression.